Læknablaðið - 15.11.2003, Qupperneq 22

FRÆÐIGREINAR / TALÍDÓMÍÐ
13. Jóhannesson Þ. Krabbameinslyf og svarbælandi lyf. Reykja-
vík: Háskólaútgáfan; 1994: 38-41.
14. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: stra-
tegies to restrain this proinflammatory cytokine. Immunol
Today 1997; 18: 487-92.
15. Stephens T, Brynner R. Dark Remedy. The impact of thalido-
mide and its revival as a vital medicine. Cambridge (Mass.):
Perseus Publishing 2001:121-3; 155-8; 161; 169; 186-9).
16. Raje N, Anderson KC. Thalidomide and immunomodulatory
drugs as cancer therapy. Curr Opin Oncol 2002; 14: 635-40.
17. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA,
Kaplan G. Thalidomide exerts its inhibitory action on tumor
necrosis factor a by enhancing mRNA degradation. J Exp
Med 1993; 177:1675-80.
18. Jin SH, Kim TI, Han DS, Shin SK, Kim WH. Thalidomide
suppresses the interleukin ip-induced NFkB signalling path-
way in colon cancer cells. Ann NY Acad Sci 2002; 973: 414-8.
19. Geitz H, Handt S, Zwingenberger K. Talidomide selectively
modulates the density of cell surface molecules involved in the
adhesion cascade. Immunopharmacol 1996; 31:213-21.
20. Corral LG, Haslett PAJ, Muller GW, Chen R, Wong LM,
Ocampo CJ, et al. Differential cytokine modulation and T cell
activation by two distinct classes of thalidomide analogues that
are potent inhibitors of TNF-a. J Immunol 1999; 163: 380-6.
21. Cavenagh JD, Oakervee H. Guideline. Thalidomide in mul-
tiple myeloma: Current status and future prospects. Brit J
Haematol 2003; 120:18-26.
22. Shannon EJ, Miranda RO, Morales MJ, Hastings RC. Inhibi-
tion of de novo IgM antibody synthesis by thalidomide as a
relevant mechanism of action in leprosy. Scand J Immunol
1981; 13: 553-62.
23. Sheskin J. Thalidomide in the treatment of lepra reactions.
Clin Pharmacol 1965; 6: 303-6.
24. Sheskin J. The treatment of lepra reaction in lepromatous
leprosy. Fifteen years’ experience with thalidomide. Int J Der-
matol 1980; 19: 318-22
25. Zeldis JB, Williams BA, Thomas SD, Elsayed MF. S.T.E.P.S.: a
comprehensive program for controlling and monitoring access
to thalidomide. Clin Ther 1999; 21: 319-30.
26. Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide
treatment for refractory Crohn’s disease: a review of the
history, pharmacological mechanisms and clinical literature.
Ann Med 2001;33:516-25.
27. Ossandon A, Cassara EAM, Priori R, Valesini G. Thalido-
mide: focus on its employment in rheumatologic diseases. Clin
Exper Rheumatol 2002; 20: 709-18.
28. Wines NY, Cooper AL, Wines MP. Thalidomide in dermato-
logy. Austral J Dermatol 2002; 43: 229-40.
29. Elliott MS, Maini RN, Feldmann M, Kalden JR, Antoni C,
Smolen JS, et al. Randomised double-blind comparison of chi-
meric monoclonal antibody to tumor necrosis factor a (cA2) ver-
sus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
30. Huang F, Wei JCC, Breban M. Thalidomide in ankylosing
spondylitis. Clin Exper Rheumatol 2002; 20 (Suppl. 28): S158-
S161.
31. Olson KB, Hall TC, Horton J, Khung CL, Hoseley HF. Thali-
domide (N-phthaloylglutarimide) in the treatment of
advanced cancer. Clin Pharmaol 1965; 6: 292-7.
32. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddel-
mon P, et al. Antitumor activity of thalidomide in refractory
multiple myeloma. N Eng J Med 1999; 341:1565-71.
33. Jaslow R, Kaplan G, Lyons L, Michaeli J, Coleman M. Thali-
domide in multiple myeloma - from the clinic to the labora-
tory. Cancer Invest 2002; 20:1051-8.
34. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R.
Thalidomide alone or with dexamethasone for previously un-
treated multiple myeloma. J Clin Oncol 2003; 21:16-9.
35. Thalidomide - a revival story (ritstjórnargrein). N Engl J Med
1999; 341:1606-9.
36. Kjartansdóttir Þ (lyfjafræðingur, Lyfjastofnun). Bréfl. uppl.
21.11.2002 og 24.2.2003.
37. Noble K. Bad drug makes good. Thalidomide, once the most
feared of medications, is now showing promise as a cancer
treatment. Time 2003 (2.3.); 53.
38. Thalidomide trials to fight cancer. BBC News World Edition
(28.1.2003).
39. Richardson P, Hideshima T, Anderson K. Thalidomide: Emer-
ging role in cancer medicine. Ann Rev Med 2002; 53: 629-57.
40. Muller GW, Chen R, Huang SY, Corral LG, Wong LM,
Patterson RT, et al. Amino-substituted thalidomide analogs:
potent inhibitors of TNF-alpha production. Bioorg Med Chem
Lett 1999; 9:1625-30.
41. Hideshima T, Chauhan D, Shirma Y, Rate N, Davies FE, Tai
YZ, et al. Thalidomide and its analogs overcome drug resis-
tance of human multiple myeloma cells to conventional the-
rapy. Blood 2000; 96: 2943-50.
846 Læknablaðið 2003/89